LeonaBio Inc（LONA）資訊與事件

$7.940

+0.050 (+0.63%)收盤時

LONA 資訊

LeonaBio to Present Lasofoxifene at Breast Cancer Summit

Athira Pharma Q1 Earnings Beat Expectations

Athira Pharma Q1 Earnings Beat Expectations

LeonaBio Appoints New Board Members to Drive Growth

LeonaBio Reports FY 2025 Financial Results

LeonaBio Secures License for Lasofoxifene Development Program

LEONABIO INC ANTICIPATES COMPLETION OF PHASE 3 LASOFOXIFENE TRIAL ENROLLMENT BY Q4 2026, WITH TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2027

LEONABIO INC: MIZUHO UPGRADES RATING TO OUTPERFORM AND INCREASES TARGET PRICE TO $10 FROM $4

2/3 07:10

LeonaBio Appoints Mark Kubik as Chief Business Officer

LeonaBio announced the appointment of Mark Kubik as Chief Business Officer. Kubik previously served as a strategic consultant to LeonaBio.

1/20 16:50

LeonaBio Files to Sell 5.5M Shares of Common Stock

LeonaBio files to sell 5.5M shares of common stock for holders

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。